Methods and compositions for delivering interleukin-1 receptor antagonist
Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
1. A method of treating inflammation in a subject, comprising:
concentrating a volume comprising white blood cells to produce a therapeutic composition, wherein the white blood cells are in the volume at a concentration of between 4,000 cells/μl and 33,000 cells/μl; and
administering the composition to a site of inflammation in the subject, wherein concentrating includes contacting the volume comprising white blood cells with polyacrylamide beads and separating the polyacrylamide beads from the volume comprising white blood cells.
2. The method of claim 1 , wherein the composition comprises interleukin-1 receptor antagonist at a concentration of at least 10,000 pg/ml.
3. The method of claim 1 , wherein concentrating further includes contacting the liquid volume with a filter.
4. The method of claim 1 , wherein the volume comprises whole blood, platelet-rich plasma, bone marrow, bone marrow aspirate, a bone marrow aspirate fraction or concentrate, a white blood cell fraction or concentrate, a huffy coat fraction, a white blood cell isolate, or a combination thereof.
5. The method of claim 1 , wherein the composition further comprises soluble tumor necrosis factor receptor 1 at a concentration of at least 1,500 pg/ml.
6. A method of treating inflammation in a subject, comprising:
contacting a volume comprising white blood cells with an activator comprising polyacrylamide beads, for a period of 6 hours or less, to generate a composition comprising at least 10,000 pg/ml interleukin-1 receptor antagonist;
separating or isolating the composition from the activator; and
administering the composition to a site of inflammation in the subject.
7. The method of claim 6 , wherein contacting further comprises passing the volume through a filter.
8. The method of claim 6 , wherein the activator comprises dry polyacrylamide beads.
9. The method of claim 6 , wherein the concentration of white blood cells in the volume is between 4000 cells/μl and 33,000 cells/μl.
10. The method of claim 6 , wherein the composition comprises at least 15,000 pg/ml interleukin-1 receptor antagonist.
11. The method of claim 6 , wherein the composition further comprises soluble tumor necrosis factor receptor 1 at a concentration of at least 1,500 pg/ml.
12. The method of claim 6 , wherein the volume comprises whole blood, platelet-rich plasma, bone marrow, bone marrow aspirate, a bone marrow aspirate fraction or concentrate, a white blood cell fraction or concentrate, a buffy coat fraction, a white blood cell isolate, or a combination thereof.
13. A method of treating inflammation in a subject, comprising:
contacting a volume of white blood cells with polyacrylamide beads, to produce a therapeutic composition comprising at least 10,000 pg/ml interleukin-1 receptor antagonist; and
administering the therapeutic composition to a site of inflammation in the subject.
14. The method of claim 13 , wherein contacting further comprises passing the volume through a filter.
15. The method of claim 13 , wherein the concentrating material comprises dry polyacrylamide beads.
16. The method of claim 13 , wherein the white blood cells in the volume are at a concentration of between 4,000 cells/μl and 33,000 cells/μl.
17. The method of claim 13 , wherein the composition comprises at least 15,000 pg/ml interleukin-1 receptor antagonist.
18. The method of claim 13 , wherein the composition further comprises soluble tumor necrosis factor receptor 1 at a concentration of at least 1,500 pg/ml.
19. The method of claim 13 , wherein the volume comprises whole blood, platelet-rich plasma, bone marrow, bone marrow aspirate, a bone marrow aspirate fraction or concentrate, a white blood cell fraction or concentrate, a huffy coat fraction, a white blood cell isolate, or a combination thereof.